Business Wire

RSA Announces CEO Transition to Lead New Phase of Growth

5.9.2025 14:00:00 EEST | Business Wire | Press release

Share

RSA, the security-first identity leader, backed by Clearlake Capital Group, L.P. (together with its affiliates) and STG, today announced that Greg Nelson, current President and Chief Business Officer, will succeed Rohit Ghai as Chief Executive Officer on September 15, 2025. Mr. Ghai will transition to a strategic advisory role after serving almost eight years as CEO.

Mr. Nelson, a seasoned SaaS executive who has more than 30 years of software, data, technology and private equity experience, is expected to lead RSA into this next phase of accelerated growth. The company’s strategic growth initiatives and investments will focus on:

  1. Passwordless – Eliminating reliance on passwords to improve security and user experience
  2. Artificial Intelligence (AI) – Leveraging AI to enhance threat detection, prevention, and response
  3. Posture Management – Strengthening governance, risk, and compliance capabilities
  4. Highest-assurance identity solutions – Protecting the most security-sensitive organizations

“With favorable market trends and clear competitive advantages, we believe RSA is uniquely positioned to accelerate its growth,” said Prashant Mehrotra, Partner and Managing Director at Clearlake Capital Group. “We are confident that Greg’s leadership and focus on innovation across these four strategic pillars will drive the company’s momentum in the years ahead.”

Mr. Nelson has been with RSA for nearly four years, reimagining the company’s go-to-market approach to be customer-first and growth-focused. In his role as CEO, Mr. Nelson will continue working to build RSA’s strong foundation to deliver innovation and scale in ways that meet the evolving needs of its global customer base.

“RSA has built momentum, and we’re ready to move faster, innovate more boldly, and scale our business to capture new opportunities,” said Mr. Nelson, incoming CEO of RSA. “We have a clear strategy, a strong market position, and the investment we need to execute. This is an incredibly exciting time for RSA, our customers, and our employees.”

Under Mr. Ghai’s leadership, RSA navigated its carve-out from Dell Technologies, separated into independent businesses, returned to growth, and modernized its core offerings. During this time the company also sharpened its focus on identity security, transformed from an on-premises point product company to a SaaS-based identity security platform, and reaffirmed its leadership in serving the world’s most security-sensitive organizations.

“Rohit has led RSA through a period of remarkable transformation,” said Ed Didier, Managing Director at STG. “He strengthened the company’s market position, built a high-performing team, and set the stage for accelerated growth under new leadership. On behalf of the Board, we would like to thank Rohit for his contribution, and we’re pleased he will continue to serve as an advisor to the company going forward.”

About RSA

RSA provides mission-critical cybersecurity solutions that protect the world’s most security-sensitive organizations. The RSA Unified Identity Platform provides true passwordless identity security, risk-based access, automated identity intelligence, and comprehensive identity governance across cloud, hybrid, and on-premises environments. More than 9,000 high-security organizations trust RSA to manage more than 60 million identities, detect threats, secure access, and enable compliance. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.

About Clearlake Capital Group, L.P.

Clearlake Capital Group is a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies. Founded in 2006, the firm has more than $90 billion of assets under management and has led or co-led over 400 investments globally. With deep knowledge and operational expertise across the technology, industrials, and consumer sectors, Clearlake seeks to partner with experienced management teams, providing patient, long-term capital and aiming to drive value through its active hands-on operating approach, O.P.S.® (Operations, People, Strategy). Headquartered in Santa Monica, Clearlake maintains a global footprint with offices in Dallas, London, Dublin, Luxembourg, Abu Dhabi, and Singapore. For more information, please visit clearlake.com or follow us on LinkedIn.

About STG

STG is a private equity partner to market leading companies in data, software, and analytics. The firm brings experience, flexibility, and resources to build strategic value and unlock the potential of innovative companies. Partnering with a goal to build customer-centric, market winning portfolio companies, STG seeks to create sustainable foundations for growth that bring value to existing and future stakeholders. The firm is dedicated to transforming and building outstanding technology companies in partnership with world class management teams. STG’s expansive portfolio has consisted of more than 50 global companies. For more information, please visit http://www.stg.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250905958809/en/

Contacts

Media Contact:
teamrsa@axicom.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye